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Abstract 
Inflammation starts whenever antigens trigger molecules and cells of the immune system causing them to move 
to the affected site. This forms part of the body's response to internal and external environmental stimuli that 
normally eliminate the offending organism or cells and restore the tissue physiology. We have previously shown 
that chronic inflammation may lead to prostate carcinogenesis in both animal and human models. Substantial 
data has shown that over 25% of all cancer cases are related to chronic inflammation, and other types of 
unresolved inflammatory processes. Further evidence for this relationship is the fact that prolonged use of non-
steroidal anti-inflammatory drugs (NSAIDs) has been associated with reduced risk to developing many types of 
cancers. Here we review current available internationally published papers in view of several reports on 
inflammation and cancer progression and draw a synthesis to provide a concise insight to the emerging field of 
inflammation and cancer. In particular, the molecular mechanisms underlying the concept of inflammation-
mediated cancer development, progression, invasion and metastasis was discussed in detail. Indeed, we provide 
details to allow readers understand the very new concept that underpin the dual host-protective and tumor-
promoting actions of cancer immunoediting and present substantial scientific data that strongly suggest that 
inflammatory markers might be potent molecular targets for cancer diagnosis, treatment, monitoring and 
prevention. 
Keywords: Inflammation, carcinogenesis, Toll-like receptors (TLR), leukocytes migration, chemokines, 
metastasis, immunoediting 
 
1. Introduction 
The quest for protection is fundamental to living 
organisms or cells. The innate immune system is 
evolutionally conserved and is the first line of the 
defensive mechanisms for protecting the host from 
invading microbial pathogens. Until recently, innate 
immunity was considered as being nonspecific 
immune responses mediated by phagocytotic cells 
such as macrophages and neutrophils that engulf 
and lyses microbial pathogens (Medzhitov et al., 
1997). Experimental evidence showed that 
Drosophila with mutations in specific genes which 
result in loss-of-function involving the Toll receptor 
developed high susceptibility to fungi infection and  
defective production of an antifungal peptide; this 
provided the initial evidence that Drosophila 
expresses a specific receptor responsible for sensing 
fungi infection (Anderson et al., 1985a; Anderson 
et al., 1985b; Lemaitre et al., 1996). Currently, 
human homolog of Toll (hToll) which is also 
known as Toll-like Receptor (TLR) was identified, 
which was shown to induce production of 
inflammatory cytokines and expression of 
costimulatory molecules (Lemaitre et al., 1996; 
Roach et al., 2005). More recently, this family of 
pattern recognition receptors has been shown to 
play a critical role in the elicitation of procancer 
and anticancer immune responses (Vacchelli et al., 
2013).  
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Table 1: showing forms of hematological malignancies and associated inflammatory markers. 
 
Therefore, understanding of this molecular 
interplay would arouse interest in the development 
of immunochemotherapeutic regimens for cancer 
therapy. The question here is why should the 
process of protection be interred- wound with 
inflammation? And how does inflammation affect 
cancer initiation, progression and metastasis and 
chemoprotection. This review therefore provides an 
insight into the concept of inflammation and cancer 
development and highlights the mechanism of 
inflammation mediated carcinogenesis with a view 
of creating better understanding that may culminate 
in developing entirely new ideas for targeted cancer 
therapy and prevention. We first present an 
overview of the innate immune signaling and 
highlight the link between innate immunity and 
adaptive immunity in health. 
2. The Toll like signaling 
Today, up to 10 different forms of TLR in human 
and 13 in mice have been identified. The TLR 
system is known to be the pathogen associated 
molecular patterns used by the innate immune 
system to identify specific pathogens, targeting 
them for destruction (Anderson et al., 1985a; 
Lemaitre et al., 1996; Vacchelli et al., 2013; 
Hoshino et al., 1999). For example, LPS 
(lipopolysaccharide) of Gram-negative bacteria is 
recognized by TLR4 (hToll) and TLR2, in concert 
with TLR1 or TLR6, recognizes various bacterial 
components, including peptidoglycan, lipopeptide 
and lipoprotein of Gram-positive bacteria and 
mycoplasma lipopeptide (Hoshino et al., 1999; 
Jiang et al., 2013). Whenever the TLR have 
recognized the specific ligand from the microbial 
pathogens, it triggers an intracellular signaling 
pathways that result in the transcription of genes 
leading to the production of inflammatory 
cytokines, like type I interferon (IFN) and 
chemokines (Vacchelli et al., 2013; Jiang et al., 
2013). In addition, signaling from TLRs induces the 
expression of costimulatory molecules on 
specialized antigen-presenting cells called dendritic 
cells (DCs). This process, called DC maturation, is 
essential for the induction of pathogen-specific 
adaptive immune responses, thus indicating that 
TLRs link innate and adaptive immunity (Hayashi 
et al., 2001). Specifically, TLRs activates a 
common signaling pathway that culminates in 
activation of NF-κB at the cytoplasm and formation 
of NF-κB complexes in the nucleus; this process is 
controlled by the activity of the IkB kinase (IKK) 
complex, which phosphorylates IkB proteins and 
bind to target DNA sequences to regulate the 
expression of genes involved in cytokine and 
chemokine induction, especially pro-inflammatory 
cytokines, such as tumor necrosis factor (TNF), IL-
1, IL-6, and IL-12 (Vacchelli et al., 2013; Jiang et 
al., 2013; Hayashi et al., 2001; Yoon et al., 2012). 
Association of these inflammatory cytokines and 
cancer promotion and its prognostic implications 
are discussed in appropriate paragraphs in this 
work. In brief, a large body of published work has 
confirmed the ability of TLR agonists to mediate 
radio-, chemo- or immunotherapy or therapeutic 
effects against a variety of tumors, including 
lymphoma, mastocytoma, glioma, breast 
carcinoma, thymoma, fibrosarcoma, head and neck 
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cancer, melanoma, lung cancer, colorectal 
carcinoma, renal cancer, and ovarian carcinoma (Lu 
et al., 2012; Garaude et al., 2012; Dewan et al., 
2012; Li et al., 2012; Betting et al., 2012; Dovedi et 
al., 2013; Peng et al., 2013); this indicates that 
TLRs play striking role in inflammation-mediated 
carcinogenesis (see table 1). Classic Hodgkin's 
lymphoma is characterized by Hodgkin and Reed-
Sternberg cells and in most cases is derived from 
germinal-centre B cells. It is generally accepted that 
infection with Epstein - Barr virus may be 
associated with the formation of Hodgkin and reed-
stemberg cells resulting in Hodgkin lymphoma. 
However the report of Thomas and colleague 
(Thomas et al., 2004) suggests that a constitutive 
activity of NF-κB in Hodgkin lymphoma cells may 
also be a feature of this form of cancer (Table 1). 
The author showed that the activity of NF-κB was 
mediated through CD40, CD30, receptor activator 
of NF-κB (RANK), and Notch surface molecules 
following TLR stimulation (Thomas et al., 2004). 
Today, due to strong link between TLR signaling 
and cancer progression, three TLR agonists are 
currently approved by FDA for use in cancer 
patients: bacillus Calmette-Guérin (BCG, an 
attenuated strain of Mycobacterium bovis initially 
developed as a vaccine against tuberculosis), which 
is currently approved for the immunotherapy of in 
situ bladder carcinoma (Hoffman et al., 2005). 
3. Inflammatory responses 
Inflammation is triggered when epithelial or stoma 
cells of infected tissue or tissue resident 
hematopoietic cells such as mast cells or DCs 
recognizing an inflammatory stimulus and 
propagating pro-inflammatory signals. These 
signals lead to the recruitment and activation of 
effector cells, initially neutrophils and later 
macrophages and other leukocytes, resulting in the 
tissue changes characteristic of inflammation - 
rubor, calor, dolor, and tumor (redness, heat, pain, 
and swelling, respectively). This may involve 
activation of the complement system and generation 
of molecules including the C5a, which together 
with C3b and C4a triggers release of some 
pharmacologically active compounds like histamine 
from activated mast cells (Roach et al., 2005; 
Vacchelli et al., 2013; Hoshino et al., 1999). These 
compounds induce increase in vascular 
permeability and contraction of the smooth muscles 
within the local microenvironment (Delves and 
Roitt, 2000). This may result in tissue damage and 
release of some molecules from the vascular 
endothelium which sends signals to cause more 
cells to pass through the vascular system to the site 
of the antigen triggering the response (Delves and 
Roitt, 2000). For example, the neutrophils contain a 
surface molecular L-seletin while an adhesion 
molecule which contains carbohydrate structures 
including sialyl-lewis located on the surface of the 
vascular endothelium recognizes and interact with 
the L-seletin when cell rolls along the vascular bed 
(Delves and Roitt, 2000). The molecular interaction 
between the L-seletin and the asialyl-lewis results 
in activation of the neutrophils and shedding off of 
the molecular and its replacement with intriguing. 
The activated neutrophil then pass through the 
vessel walls to the site of the antigen causing the 
response (Delves and Roitt, 2000). The process is 
known as extravasations of leukocytes and it's a 
known feature of progressive and invasive cancer 
state (Omabe and Onyekachi, 2013). This event 
allows different forms of leukocytes and soluble 
molecules to migrate to the site of the 
inflammation, making the area to have a number of 
features in common with the molecular picture of 
the tumor microenvironment (Omabe and 
Onyekachi, 2013), figure 1. 
4. Inflammation and cancer 
initiation 
Evidence from published studies few years back 
has continued to stimulate a hot debate concerning 
the role of inflammation and risk of developing 
malignant cancer disease. Although early study 
within last decade had observed persistence of 
inflammatory cells within tumor environment, 
recently, reports from the authors' laboratory 
demonstrated a strong link between infection, and 
conditions associated with inflammatory states 
(Omabe and Ezeani, 2011); that report pointed out 
that lack of access to anti inflammatory agents was 
a key factor that predispose to carcinogenesis in 
both experimental and clinical studies (Omabe and 
Ezeani, 2011). Since then there have been more 
than 100 published articles addressing the role of 
inflammation and cancer progression. Currently, it 
is becoming clearer that inflammation may have 
important role in various forms and stages of 
tumorigenesis. It was widely accepted that cancer 
was a genetic disease that run through families; 
however, available knowledge today suggest that 
causes of cancer due to genetic inheritance may just 
be about 10% of all cases - this means that up to 25 
- 50% of cancer cases might be as a result of 
environmental influences which may induce 
inflammatory states in its molecular pathogenesis 
(Borroni et al., 2009). Due to lack of full 
understanding of the parts played by inflammation 
in carcinogenesis, many authors provide conflicting 
statistics regarding the actual percent of cancer 
cases that are due to inflammatory conditions. For 
example while many suggest that inflammation 
causes up to 30% of cancer cases, others quote 
dietary factors to be responsible for 35% cases.  
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Figure 1: showing the tumor microenvironment characterized with alteration in redox signaling and increased level of hypoxia, 
demonstrated here with increased immunopositivity of Glut-1 antibody (the dark-brown cells) cells with blue staining are non 
hypoxic. This feature is also found in the tissues with chronic inflammation. 
 
But reports from published studies explained that 
dietary products may initiate tumorigenesis by first 
stimulating inflammatory response (Omabe and 
Ezeani, 2011; Omabe et al., 2012). In addition, 
tobacco is generally accepted as a known cancer 
initiator and would be categorized with a significant 
percentage (Omabe et al., 2012). However 
emerging evidence now indicates that tobacco 
smoke also promote carcinogenesis due to its 
ability to trigger chronic inflammation (Takahashi 
et al., 2010). 
5. Inflammation and solid tumor 
5.1. Leukocyte migration promotes cancer 
progression 
Available evidence suggest that cells found in the 
microenvironment of tumors often resembles that 
seen in histology of tissues from chronic 
inflammation and that increased numbers of 
neutrophils may be associated with such tumors; 
these may have implication on prognosis (figure 2). 
Neutrophil recruitment into tumors appears to be 
dependent on chemokines that bind to CC, CXCR1 
and CXCR2 commonly expressed by neutrophils 
(figure 2). Thus, chemokine (C-X-C motif) ligand 1 
(CXCL1) and its receptor CXCR2 are associated 
with metastasis potential. Tazzyman and colleagues 
(Tazzyman et al., 2011) showed that significant 
reduction in the numbers of infiltrating neutrophils 
into both in vitro and in vivo tumor models was 
associated with slower growth of lung tumors. 
Neutrophil infiltration into A549 tumor spheroids 
increased their size compared to noninfiltrated 
spheroids (Tazzyman et al., 2011) The author 
showed that neutrophils may contribute to lung 
tumor growth and that CXCR2 antagonists may be 
a useful therapeutic agent in the treatment of lung 
carcinomas (figure 2). In a clinical study that 
involved the use of quantitative PCR and 
immunohistochemistry techniques, Cheng and 
colleagues (Cheng et al., 2011) investigated the 
functional significance of CXCL1 expression. The 
author clearly demonstrated that up regulation of 
CXCL1 correlated significantly with tumor 
progression, advanced stage of gastric cancer 
patients, and was one of the independent prognostic 
factors for patient's survival. Furthermore, cancer 
cells expressing CXCL1 stably exhibited an 
increase in cell migration and invasion ability, 
whereas CXCL1 or CXCR2 depletion significantly 
reduced the migration and invasion ability of each 
cell line (Cheng et al., 2011). In addition, by 
selectively targeting the inflammatory marker 
CXCR2/CXCR1 with orally active small-molecule 
inhibitors, an aggressive skin cancer showed 
significant (P < 0.05) decreases in tumor cell 
proliferation and micro vessel density in tumors. 
Moreover, further experiments in that study 
suggested another significant increase in melanoma 
cell apoptosis compared with the controls (Singh et 
al., 2009). Another study which also clearly 
demonstrated that CXCR2 was protumorigenic 
chemokine receptor, that directs recruitment of 
tumor-promoting leukocytes into tissues during 
tumor-inducing and tumor-driven inflammation. 
Jamieson and colleagues (Jamieson et al., 2012), 
showed that blockade of CXCR2 profoundly 
suppressed inflammation-driven tumorigenesis in 
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skin and intestine as well as spontaneous 
adenocarcinoma formation even in a model of 
invasive intestinal adenocarcinoma (Jamieson et al., 
2012) see figure 2.  
Further experimental evidence showed that CXCR2 
deficiency was associated with profound 
suppression inflammation-driven tumorigenesis in 
skin and intestine as well as spontaneous 
adenocarcinoma formation in a model of invasive 
intestinal adenocarcinoma and that CXCR2 
inhibition reduced tumorigenesis in mice (Jamieson 
et al., 2012). It is thought that CXCR2 influences 
tumor through multiple mechanisms and might 
promote tumor development (Jamieson et al., 
2012). In addition, sufficient leukocyte populations 
were found in human intestinal adenomas, 
suggesting that inflammation by migratory 
leukocytes may induce tumor development 
(Jamieson et al., 2012). 
5.2. Macrophage infiltration and cancer 
The role of macrophages in tumorogenesis is 
complex because there are indications that they can 
both prevent and promote tumor development. 
Tumor-associated macrophages are one of the 
major constituents of tumor stroma in many solid 
tumors and there is compelling preclinical and 
clinical evidence that macrophages promote cancer 
initiation and malignant progression (Dun et al.,  
2013). Recently, Dun and colleague (Dun et al., 
2013) investigated whether macrophage distribution 
or its density differed among normal endometrial 
tissue, hyperplasia, Type I, and II endometrial 
adenocarcinomas. By analyzing pathologic 
specimens of women who underwent hysterectomy 
for benign disorders, endometrial hyperplasia, Type 
I, or Type II cancers stained with anti-CD68 
antibody; the author demonstrated that type I and II 
endometrial carcinomas sections had significantly 
higher macrophage density in both epithelial and 
stoma compartments compared with the benign 
endometrium (Dun et al., 2013).  
However, in that study, it was shown that in both 
benign and neoplastic specimens, that the numbers 
of macrophages were significantly higher in the 
stroma compared with the epithelium, surprisingly, 
the patients' cancer progression did not correlate 
significantly with the number of TAMs.  
Previous report indicate that tumor-associated 
macrophages (TAMs) recruited to the tumor 
microenvironment (figure 1), play important role in 
the progression of cancer.  
There is strong evidence for an inverse relationship 
between TAM density and clinical prognosis in 
solid tumors of the breast, prostate, ovary, and 
cervix, but not endometrial cancer (Dun et al., 
2013). 
 
 
Figure 2: illustrating how neutrophils recruitment into tumor contributes to aggressive malignant cancer behavior and to 
prognostic index. Cancer cells expressing increased level of CXCL1 or CXCR2 acquire more malignant potential and ability to 
migrate to distant organs; this suggests that by inhibiting the CXC1 or CXCR2 receptors, cancer invasive characteristics may be 
abrogated; this may result in improved survival index. 
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Figure 3: showing the consequences of chemokine receptor decoy D6 expression and the risk of developing or being protected 
from inflammation mediated cancer. 
 
 
5.3. Nutrition, inflammation and cancer 
The report of Nelson and colleagues (Nelson et al., 
2003) had shown that heterocyclic amines for 
example, amino-1-methyl-6-phenylimidazo [4, 5-b] 
pyridine (PhIP) contained in roasted meat or fish 
may contribute to prostate carcinogenesis. Also rats 
exposed to this product through their diet developed 
intestine, mammary, and prostate cancer (Sugimura 
et al., 2004). A 12 weeks exposure of PhIP also 
resulted in increased mast cell and macrophage 
infiltration, epithelial atrophy of the ventral lobe, 
followed by prostatic intraepithelial neoplasm 
(PIN) in rats (De Marzo et al., 2007). Borowsky et 
al (Borowsky et al., 2006) used rat as a model of 
human prostate cancer and studied the mechanism 
of prostate cancer development following exposure 
to PhIP. This study strongly demonstrates that the 
pathogenesis of prostatic neoplasia following 
exposure with this product occurred through 
inflammation and post-inflammation proliferative 
atrophy. 
5.4. Cytokines and carcinogenesis 
Chemokines are multifunctional secreted peptides 
that play an important role in regulating leukocyte 
migration. They are divided into 4 subgroups (CC, 
CXC, CX3C, and XC) according to a characteristic 
cysteine motif. The atypical chemokine receptor D6 
is a decoy and scavenger receptor for most 
inflammatory CC chemokines (Aoi et al., 2011). In 
fact, the appropriate control of the chemokine 
system involves several chemokine decoy 
receptors, with distinct specificity and tissue 
distribution, defined as nonactivating chemokine 
receptors able to bind the ligands and target them to 
degradation. The best-characterized representative 
of these receptors is D6, which is located on 
lymphatic endothelium and controls most 
inflammatory CC chemokines (Aoi et al., 2011). In 
health, the D6, has been shown to abrogate CC 
chemokines which is known to mediate 
inflammatory response; by this shut off 
inflammation by making the chemokines 
unavailable (Aoi et al., 2011; Nibbs et al., 2007) 
(see figure 3). CC chemokines are known to act 
through CC chemokine receptors (CCRs) 1 to 5, 
and contributes in modulating inflammatory 
responses (figure 3); this response is destroyed by 
chemokine D6 (Aoi et al., 2011). This phenomenon 
is critical for effective resolution of inflammation in 
vivo (Nibbs et al., 2007). For example, evidence 
from experimental studies demonstrated that mice 
deficient of D6 had increased susceptibility to 
developing cancer induced by the inflammation-
producing carcinogen, the phorbol ester (Nibbs et 
al., 2007). In contrast, transgenic mice with lots of 
D6 are resistant to tumor formation (Nibbs et al., 
2007). Lack of the D6 receptors which shuts down 
inflammatory response from CC chemokine ligand-
3 (CCL3) attracts aberrantly (in excess and for a 
longer time) CD3+ T cells and mast cell (figure 3). 
This strongly suggests that. Inflammation can be 
protumorigenic (figure 3). In fact the molecular 
mechanism by which inflammatory response might 
result in tumorigenesis has been reviewed 
extensively in a previous report by the current 
author (Omabe and Ezeani, 2011). 
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Figure 4: showing how infiltration of tumor with particular phenotypes of the leukocytes including Foxp3+ Treg cells, CD4 + cells 
and mast cells may contribute in predicting tumor invasiveness and metastasis. 
 
5.5. Inflammation promotes invasion and 
metastasis 
Abundant published evidence suggests that tumor 
progression is not only directed by genetic changes 
intrinsic to cancer cells (Omabe and Ezeani, 2011). 
We have previously reported that there is both 
molecular basis for cancer initiation and 
progression (Omabe and Ezeani, 2011; Omabe et 
al., 2012; Omabe and Okorocha, 2011). In fact our 
previous report suggests an important role for 
environmental factors including inflammation for 
carcinogenesis. Previous paragraphs has deciphered 
molecular basis of innate signaling in health and its 
association in inflammation. In addition, sufficient 
evidence linking inflammation and cancer have 
been presented in different forms of cancer. In a 
study involving 250 primary breast and prostate 
tumors, in which the primary immune cell 
especially the cytotoxic T-lymphocytes (CTL), 
Natural killer cells (NK) and Mast cells were 
analyzed by immunohistochemistry, fluorescent 
labeling and apoptosis assay, to assess the effects of 
physical disruption of the forenamed immune cells 
and potential impact on the epithelial capsule of 
human breast and prostate tumors. It was shown 
that at the early stage of tumor invasion, CTL, NK 
and Mast cells were the main types of tumor 
infiltrating immune cells involved in focal 
degenerative products of tumor capsules (Jiang et 
al., 2013; Yuan et al., 2013). In these two 
independent studies, luminal cells overlying focally 
disrupted basal cell layers had a substantially 
increased proliferation rate and elevated expression 
of stem cell markers compared to their adjacent 
morphologically similar counterparts that overlie a 
non-disrupted capsule (Yuan et al., 2013), 
suggesting that these inflammatory cells may 
contribute to aggressive and invasive tumor 
progression. The primary function of these 
infiltrating leukocytes was associated with focal 
disruptions of the tumor capsule, which selectively 
favor tumor stem cells proliferation, invasion and 
metastasis (Jiang et al., 2013; Yuan et al., 2013). 
The CD4 (+) T cells, CD8 (+) T cells, and forkhead 
box P3-positive (Foxp3) regulatory T cells (Tregs) 
are the keys cells involved in immune surveillance 
and tolerance, respectively. The effects of the 
complex interaction between these cell types and 
the clinical outcome are not clearly understood. A 
most recent study found significant correlations 
between increased immunosensitivity for Foxp3(+) 
Treg/CD4(+) T-cell ratio and lymph node 
metastasis (figure 4) and Ki-67 (P= 0.003) and 
triple-negative breast cancer (P=0.004) (Kim et al., 
2011). This suggests that the increased number of 
Foxp3 (+) Tregs was significantly associated with 
lymph node metastasis and increased cell 
proliferation (Kim et al., 2013) (see figure 4). Of 
note, in the study was that lower Foxp3 (+) 
Treg/CD4 (+) T-cell ratio was significantly 
associated with triple negative breast cancer. 
5.6. The central role of NFκB and IKK 
activation and carcinogenesis 
NF-κB is responsible for the transcription of the 
genes encoding many pro-inflammatory cytokines 
and chemokines. The pathway from pathogen 
recognition to pro-inflammatory cytokine 
production demonstrates a particular reliance on 
NF-κB. A role for NF-κB in cancer is supported 
from numerous reports showing that NF-κB is 
activated (i.e., nuclear) in a number of tumors. NF-
κB activation has been reported in cancer including 
hematological malignancies. Nuclear factor kappa 
B (NF-κB) is as a transcription factor present in the 
nucleus of B cells that bound to the enhancer of the 
k light chain of immunoglobulins (Ghosh and 
Karin, 2002). NF-κB stimulates the expression of a 
panel of antiapoptotic gene products including 
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FLICE inhibitory protein (FLIP), cIAP, survivin, B-
cell leukemia/lymphoma 2 (Bcl-2), and Bcl-XL, 
underscoring its importance on cell death in 
hematologic malignancies. Once activated, NF-κB 
dissociates into NF and κB, allowing NF to 
translocate to the nucleus; this activates more than 
200 specific genes involved in cell survival, 
apoptosis, and active immunity. It is clear that NF-
κB is directly involved in both cellular responses 
that culminate in production of cytokines and 
inflammation. We have previously shown that 
inflammation might be one of the several ways 
responsible for cancer initiation and progression in 
prostate gland (Omabe and Ezeani, 2011). In 
particular, inflammatory breast cancer (IBC) is the 
most aggressive form of locally advanced breast 
cancer with a high metastatic potential. At the 
molecular level, microarray and qPCR analysis 
have revealed an 'NF-κB signature' in IBC 
(Lerebours, 2008). Interestingly, the first piece of 
evidence implicating IKK in tumor development 
was in breast cancer. IKK was found to be 
constitutively expressed in two-thirds of the human 
breast cancer tissues analyzed, as well as in several 
human breast cancer cell lines (Lerebours, 2008). 
6. Inflammation and cancer 
suppression 
6.1. Immunosurveillance, immunoediting and 
cancer 
By treating mouse with [7, 12-
dimethylbenz[a]anthracene (DMBA)/12-O-
tetradecanoylphorbol 13-acetate (TPA)], a mouse 
model of carcinogenesis (skin papilla ma) with 
proinflammatory processes is created 
experimentally (Rakoff-Nahoum and Medzhitov, 
2007; Swann et al., 2008). The [3'-
methylcholanthrene (MCA)] is a different chemical 
for inducing fibrosarcoma model which is used to 
illustrate innate and adaptive immune surveillance 
of cancer and for investigating the existence of 
cancer immunoediting process (Rakoff-Nahoum 
and Medzhitov, 2007; Swann et al., 2008). To show 
that immunoediting exists to protect one from 
tumorigenesis, Swann and colleagues (Swann et al., 
2008) exposed mice to a combination of DMBA 
and proinflammatory TPA stimuli; the author 
showed that mice lacking MyD88 (which acts 
downstream following TLR activation) formed 
fewer tumors than genetically matched inbred WT 
C57BL/6 (WT) controls treated in a similar manner, 
indicating that inflammation-mediated 
carcinogenesis was repressed due to lack of MyD88 
molecule (Swann et al., 2008). However evidence 
from investigations in that study also revealed that 
MyD88-/- mice also formed fewer tumors than WT 
controls when exposed to MCA, indicating that the 
process of immunoediting operates to repress tumor 
formation. That study also demonstrated the 
coexistence of inflammation-dependent tumor 
induction by MyD88, as well as the occurrence of 
the process of cancer 
immunosurveillance/immunoediting, known to be 
driven by cytokines known to be regulated by 
MyD88 (TNFα and IFN-α/β) in the same animal 
(Pagès et al., 2005). Immunoediting is therefore the 
process by which innate and adaptive immunity 
work together to eliminate primary chemically 
induced or spontaneous tumors or to promote tumor 
outgrowth by mechanisms involving the dampening 
of tumor immunogenicity or attenuation of the 
protective antitumor response (Rakoff-Nahoum and 
Medzhitov, 2007; Swann et al., 2008). Together, 
the dual host-protective and tumor-promoting 
actions of immunity are referred to as cancer 
immunoediting and comprised of three distinct 
phases: elimination, equilibrium, and escape. 
6.2. Tumor T memory cell, immunoediting and 
clinical outcome 
Cancer immunoediting involves principally the 
lymphocytes of the adaptive immune system, with 
the physiologic function of protecting the host from 
the development of cancer and altering tumor 
progression by driving the outgrowth of tumor cells 
with decreased sensitivity to immune attack. The 
elimination phase of cancer immunoediting is not 
clearly understood, however there are indications 
that this process might be a continuous process 
which could be critical for cancer progression and 
survival indices. From general understanding of 
basic immunology, it is a common knowledge that 
T cells differentiate into type 1 or type 2 helper T 
cells (Th1 and Th2, respectively) after the 
expression of T-BET (T-box transcription factor 
21) or GATA-3, respectively. Protective immune 
responses are mediated by effector memory T cells 
subpopulation with CD8+, CD45RO+, CCR7- 
(negative for CC chemokine receptor 7), CD62L- 
(negative for CD62 ligand), perforin+, granulysin+, 
granzyme B+ phenotypes. Stimulation with an 
antigen induces these cells to exert an immediate 
effector function by releasing cytotoxic mediators. 
In a clinical study, Pages et al (Pagès et al., 2005) 
demonstrated that infiltration with leukocytes 
including the T cell memory was associated with 
cancer survival. In particular, data from the analysis 
of 39 colorectal cancers cases showed that presence 
of effector memory T cells within the tumor, 
defined by the presence of CD3, CD8, CD45RO, 
CCR7, CD28, and CD27 markers, was associated 
with absence of tumor metastasis which correlated 
with a good clinical outcome (Pagès et al., 2005). 
This means T memory subpopulations may be 
involved in the process of immunoediting which 
tends to repress tumor progression. 
In a separate study, Camus et al. also demonstrated 
that co expression of genes mediating cytotoxicity 
and Th1 adaptive immune responses accurately 
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predicted patient survival independently of the 
metastatic status (Camus et al., 2009). The Author 
observed significant positive correlations between 
markers of innate immune cells [tumor-associated 
macrophages, dendritic cells, natural killer (NK) 
cells, and NK cells]. There is no full explanation 
yet for involvement of NK and dendric cells in 
immunoediting. A related study also showed that 
decreased number of CD8 (+) T cells was 
significantly associated with tumors with lymph 
node metastasis (P=0.027), higher stage (stage III, 
P=0.013), and immunopositivity of Ki-67 
(P=0.026) (Kim et al., 2013).  
Put together, these suggest that efficient 
coordination of the intratumoral immune response 
may predict a favorable outcome in solid cancers. It 
appears that recognition of tumor-specific antigens 
by lymphocytes may be involved in the process of 
immunoediting against cancer cells.  
Put together, current data suggest that infiltration of 
tumor T memory effector cells especially those with 
gene expression profile for granzymes activity, 
performing, and granulysin which are known to 
have higher capacity for releasing cytotoxic 
compounds may be associated with good clinical 
outcome in patients with colorectal cancer. 
Available data from literature suggest that 
leukocytes of the particular phenotypes are 
seriously involved in immunoediting. 
6.3. High CD8+/Foxp3 ratio and presence of 
CD45R0+ T lymphocytes predicts better overall 
survival 
As discussed above, the presence of tumor-
infiltrating lymphocytes (TIL) may be of prognostic 
importance in a variety of malignancies. A recent 
study determined the prognostic value of CD8 (+) 
cytotoxic T-lymphocytes (CTL), FoxP3 (+) 
regulatory T-lymphocytes (Treg) and CD45R0 (+) 
memory T-lymphocytes in endometrial cancer. The 
author found that high numbers of intra-tumoral 
CD8(+) T-lymphocytes and the presence of 
CD45R0(+) T-lymphocytes were all strongly 
associated with well-known favorable prognostic 
factors in endometrial cancer (de Jong et al., 2009). 
Furthermore, high numbers of CD8(+) T-
lymphocytes and a high CD8(+)/FoxP3(+) ratio 
were associated with a better disease free survival 
(DFS), and high numbers of CD8(+) T-
lymphocytes plus the presence of CD45R0(+) T-
lymphocytes were associated with a prolonged 
overall survival (OS) (de Jong et al., 2009).  
Clearly, that study showed that the presence of TIL 
was an independent prognostic factor in 
endometrial cancer and suggests that some 
infiltrated cells may play important role in 
immunoediting and cancer prevention in 
endometrial cancer. 
 
 
6.4. Role of granxymes and cancer 
Cytotoxic T cells (CTL) and natural killer (NK) 
cells recognize and kill virus-infected or 
transformed cells through two major pathways: 
either through introduction of a battery of proteases 
to the target cell cytosol; these proteases are called 
granzymes, or through TNF superfamily-dependent 
killing (Lopez et al., 2013).  
Granzymes are a family of functionally diverse and 
structurally related serine proteases that differ 
markedly in their substrate specificities which have 
been traditionally believed to be cytotoxic in nature 
and stored, along with the pore-forming protein 
perforin in the granules of cytotoxic lymphocytes 
and natural killer cells (Lopez et al., 2013). 
Although they were discovered over two decades 
ago, there remain many unanswered questions as to 
the precise roles of granzymes in physiology and 
pathology.  
To date, there are 5 human granzymes (A, B, H, K, 
M) which are thought to be involved in ensuring 
efficient immune-mediated killing of unwanted 
cells that could otherwise be resistant to the 
proteolytic activity of a single granzyme (Lopez et 
al., 2013; Bian et al., 2013). The pore-forming 
protein perforin is critical for the delivery of 
granyzmes into target cells before a cell death could 
be triggered (Bian et al., 2013).  
Elevated levels of circulating extracellular 
granzymes A and B have been linked with various 
inflammatory conditions and diseases (Bian et al., 
2013). When activated cells recognizes a target, 
cytotoxic granules within the cytoplasm move 
along microtubules to polarize at the plasma 
membrane, adjacent to the target, where they are 
secreted into the immunological synapse between 
the two cells (Lopez et al., 2013).  
Although a large body of evidence implicates 
cytotoxic granule constituents in pathways resulting 
in target cell death, recent evidence suggests that 
these granzymes may also serve alternative 
functions as initiators or amplifiers of inflammatory 
responses. 
6.5. Granzymes mediate immunoediting 
There are abundant reported cases that support 
involvement of granzymes and perforins in efficient 
immunoediting. Example, evidence from 
experimental studies have shown that mice 
deficient of either perforin or granzymes developed 
spontaneous tumor (Smyth et al., 2000; Shankaran 
et al., 2001). Mice with lack of granzymes also 
developed spontaneous tumor while more than half 
of mice deficient of perforin also developed tumor 
quicker when exposed to carcinogens (Smyth et al., 
2000; Shankaran et al., 2001). These evidences 
therefore strongly suggest that granzymes and 
perforins may have a central role in immunoediting. 
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7. Inflammations as a 
chemotherapeutic molecular 
target for treatment and 
monitoring 
7.1. Targeting inflammatory markers for cancer 
treatments and prevention 
Studies reporting reduced cancer incidence in 
patients undergoing treatment with anti-
inflammatory drugs provided the most convincing 
evidence for a role of inflammation (Omabe and 
Ezeani, 2011), this is because anti-inflammatory 
compounds inhibit cyclooxygenase-2 (Cox-2) 
activity, since this enzyme is the primary target for 
prevention of inflammation (Tabriz et al., 2013). 
For example, in transitional cell carcinoma (TCC), 
cyclooxygenase (COX)-2 has been reported as an 
attractive therapeutic target. A cross-sectional study 
involving ninety-two paraffin embedded blocks, 
which were selected from patients with urinary 
bladder TCC who underwent cystectomy or 
transurethral resection (TUR), evaluated the 
expression of COX-2 and its association with 
several clinicopathological characteristics of the 
tumor, showed that COX-2 was expressed in 50 % 
of the patients investigated (Tabriz et al., 2013). It 
was also found that COX-2 was markedly 
expressed in high grade bladder TCC (62.1%) 
versus other grades and that there was statistically 
significant difference in COX-2 expression between 
various grades (p=0.008) (Tabriz et al., 2013). In 
addition, lymphatic and perineurial invasion were 
associated with the expression of COX-2 (p=0.001, 
0.015 and 0.039, respectively) (Tabriz et al., 2013). 
However, other parameters such as stage, tumor 
size, venous invasion and lymph node metastasis 
did not show any significant relationship with this 
marker (Tabriz et al., 2013). That study strongly 
suggests that the inflammatory marker, COX-2 was 
expressed in urinary bladder TCC especially in high 
grade forms, indicating that inflammation may have 
a probable role in the differentiation of this tumor. 
From the available reports, there are reasons to 
suggest that COX-2 might be a valuable biological 
target molecule (see figure 5) in the evaluation and 
treatment of patients with bladder TCC, since high 
grade cancers show increased level of this 
inflammatory marker. It follows therefore that 
inhibition of inflammation may abrogate cancer 
development (figure 5). In addition, by treating 
mice with a combination of 2% dextran sulfate 
sodium (DSS) and azoxymethane (AOM), colon 
cancer was induced with profound production of 
inflammatory cytokines, i.e., interleukin-12 and 
tumor necrosis factor-α (TNF-α); however, 
whenever the mice were treated with 4-vinyl-2,6-
dimethoxyphenol (canolol), a potent anti-
inflammation agent obtained from crude canola oil, 
those mice developed a reduced occurrence of 
cancer, to 60%, compared with control mice, 100% 
of which had colon cancer (Fang et al., 2013). In 
that study, the numbers of tumors in each mouse 
were also significantly reduced in mice that 
received the canolol-containing diet (5.6 ± 2.0) 
compared with AOM/DSS control mice (10.8 ± 
4.2). Moreover, inflammatory cytokines (i.e., COX-
2, inducible nitric oxide synthase, TNF-α) and 
oxidative responding molecules, i.e., heme 
oxygenase-1 in colon were all suppressed during 
this treatment with the anti-inflammatory 
compound canolol (Fang et al., 2013). These 
studies strongly show that by targeting key 
inflammatory markers in the tumor 
microenvironment, neoplastic development, 
progression and metastasis would be controlled 
(figure 5). 
Furthermore, we have recently shown that the 
tumor microenvironment was associated with 
substantial features of inflammatory marker 
including hypoxia and oncogenic activities (Omabe 
and Onyekachi, 2013) (figure 1). Another 
preclinical study that involved combining dosage of 
celecoxib (a known cox-2 inhibitor) and a dietary 
fats, n-3 polyunsaturated fatty acids (PUFA) often 
found in fish oil (which exerts cancer chemo 
preventive effect mediated through COX-2 
inhibition); revealed that pretreatment of 
carcinogen-treated animals with celecoxib and/or 
fish oil altered inflammation mediated redox 
signaling with reduced c-myc, p53 expression, 
apoptosis, and proliferation in breast cancer model 
(Negi et al., 2013). However, a combination dosage 
of celecoxib and fish oil treatment in that study 
resulted in better chemo preventive effect in the 
female Wistar rats (Negi et al., 2013). The results 
suggest that a combination of celecoxib and fish oil 
which provide better anti-inflammatory synergy 
would be more effective in the chemoprevention of 
experimental mammary carcinogenesis, and this 
effect can be attributed to the modification of redox 
signaling. However, a large historical cohort study 
found no evidence of an association between non-
aspirin non steroidal anti-inflammatory drug 
(NSAID) or aspirin use and cervical cancer risk 
(Wilson et al., 2013). Put together, there are strong 
evidence to suggest that inflammation, (marked 
with COX-2 expression) may mediate 
carcinogenesis in both animal and clinical models 
(figure 2 and 3), and that anti-inflammatory agents 
may abrogate cancer development (figure 5) and 
improve disease free survival among cancer 
patients (figure 1-4). 
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Table 2: Recent clinical biological agents in clinical trials targeting inflammatory molecules for cancer treatment, adapted and 
modified from Vacchelli et al., 2013. 
 
 
Furthermore, the role of TLR molecules in NF-κB 
activation and proinflammatory chemokine 
production and their participation in cancer 
development and progression have been discussed 
(table 1 and figure 1-4).  
Emerging data show that this family of pattern 
recognition receptors has been attributed a critical 
role in the elicitation of anticancer immune 
responses; in response to this, some 
immunochemotherapeutic regimens based on 
natural or synthetic TLR agonists have been 
developed, some of which are in several stages of 
clinical trials, (table 2).  
It is hoped that in the near future, more 
inflammatory based therapies either biological 
(table 2) of chemical compounds (figure 5) would 
be developed for cancer treatment. 
In conclusion, there are sufficient convincing data 
that suggest that inflammation induces and 
promotes cancer.  
The current work provides new algorithms to 
clarify different ways inflammation may result in 
carcinogenesis and cancer control; this allows 
scientists, new and old and clinicians involved in 
cancer management to have a concise 
understanding of some emerging issues in 
oncoimmunotherapy.  
In addition, various new facets and molecular target 
onto which diagnosis, treatment and monitoring and 
drug design may be focused have been discussed. 
The understanding of the complex nature of 
immunoediting which is an emerging concept in 
oncoimmunology may evolve to yet a new horizon 
in cancer research and management.  
Importantly, some drugs are currently being 
designed (table 2) to target a number of both 
biological and biochemical markers (table 1) 
involved in spearheading inflammation dependent 
cancer progression.  
Sufficient data indicate that availability and 
accessibility of various anti-inflammatory agents 
would contribute much to cancer prevention. 
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Figure 5: showing immunohistochemical co-localisation of ki-67 in xenograft tumours. A shows control tumour without anti-
inflammatory treatment, with increased expression of Ki-67, indicating malignant cancer progression. B shows reduction of ki-67 
expression after treatment with Cox -2 inhibitor, indicating reduced cancer progression and tumour control. Produced from the 
Laboratory of Dr. Maxwell Omabe. 
 
References 
Anderson KV, Bokla L, Nüsslein-Volhard C. Establishment 
of dorsal-ventral polarity in the Drosophila embryo: the 
induction of polarity by the Toll gene product. Cell. 1985a 
Oct;42(3):791-8 
Anderson KV, Jürgens G, Nüsslein-Volhard C. 
Establishment of dorsal-ventral polarity in the Drosophila 
embryo: genetic studies on the role of the Toll gene 
product. Cell. 1985b Oct;42(3):779-89 
Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann 
JA. The dorsoventral regulatory gene cassette 
spätzle/Toll/cactus controls the potent antifungal response 
in Drosophila adults. Cell. 1996 Sep 20;86(6):973-83 
Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A 
human homologue of the Drosophila Toll protein signals 
activation of adaptive immunity. Nature. 1997 Jul 
24;388(6640):394-7 
Zucca E, Roggero E, Pileri S. B-cell lymphoma of MALT 
type: a review with special emphasis on diagnostic and 
management problems of low-grade gastric tumours. Br J 
Haematol. 1998 Jan;100(1):3-14 
Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, 
Takeda Y, Takeda K, Akira S. Cutting edge: Toll-like 
receptor 4 (TLR4)-deficient mice are hyporesponsive to 
lipopolysaccharide: evidence for TLR4 as the Lps gene 
product. J Immunol. 1999 Apr 1;162(7):3749-52 
Delves PJ, Roitt IM. The immune system. First of two 
parts. N Engl J Med. 2000 Jul 6;343(1):37-49 
Smyth MJ, Thia KY, Street SE, Cretney E, Trapani JA, 
Taniguchi M, Kawano T, Pelikan SB, Crowe NY, Godfrey 
DI. Differential tumor surveillance by natural killer (NK) and 
NKT cells. J Exp Med. 2000 Feb 21;191(4):661-8 
Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, 
Goodlett DR, Eng JK, Akira S, Underhill DM, Aderem A. 
The innate immune response to bacterial flagellin is 
mediated by Toll-like receptor 5. Nature. 2001 Apr 
26;410(6832):1099-103 
Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, 
Old LJ, Schreiber RD. IFNgamma and lymphocytes 
prevent primary tumour development and shape tumour 
immunogenicity. Nature. 2001 Apr 26;410(6832):1107-11 
Baumgartner B, Weber M, Quirling M, Fischer C, Page S, 
Adam M, Von Schilling C, Waterhouse C, Schmid C, 
Neumeier D, Brand K. Increased IkappaB kinase activity is 
associated with activated NF-kappaB in acute myeloid 
blasts. Leukemia. 2002 Oct;16(10):2062-71 
Ghosh S, Karin M. Missing pieces in the NF-kappaB 
puzzle. Cell. 2002 Apr;109 Suppl:S81-96 
Nelson WG, De Marzo AM, Isaacs WB.. Prostate cancer. 
N. Engl. J. Med. 2003;349(4):366-81. 
Bueso-Ramos CE, Rocha FC, Shishodia S, Medeiros LJ, 
Kantarjian HM, Vadhan-Raj S, Estrov Z, Smith TL, Nguyen 
MH, Aggarwal BB.. Expression of constitutively active 
nuclear-kappa B RelA transcription factor in blasts of acute 
myeloid leukemia. Hum Pathol. 2004 Feb;35(2):246-53. 
Cuni S, Perez-Aciego P, Perez-Chacon G, Vargas JA, 
Sanchez A, Martin-Saavedra FM, Ballester S, Garcia-
Marco J, Jorda J, Durantez A.. A sustained activation of 
PI3K/NF-kappaB pathway is critical for the survival of 
chronic lymphocytic leukemia B cells. Leukemia. 2004 
Aug;18(8):1391-400. 
Sugimura T, Wakabayashi K, Nakagama H, Nagao M.. 
Heterocyclic amines: Mutagens/carcinogens produced 
during cooking of meat and fish. Cancer Sci. 2004 
Apr;95(4):290-9. (REVIEW) 
Thomas RK, Re D, Wolf J, Diehl V.. Part I: Hodgkin's 
lymphoma--molecular biology of Hodgkin and Reed-
Sternberg cells. Lancet Oncol. 2004 Jan;5(1):11-8. 
(REVIEW) 
Escobar-Diaz E, Lopez-Mart¡n EM, Hernandez del Cerro 
M, Puig-Kroger A, Soto-Cerrato V, Montaner B, Giralt E, 
Garcia-Marco JA, Perez-Tom s R, Garcia-Pardo A.. 
AT514, a cyclic depsipeptide from Serratia marcescens, 
induces apoptosis of B-chronic lymphocytic leukemia cells: 
interference with the Akt/NF-kappaB survival pathway. 
Leukemia. 2005 Apr;19(4):572-9. 
Frelin C, Imbert V, Griessinger E, Peyron AC, Rochet N, 
Philip P, Dageville C, Sirvent A, Hummelsberger M, Berard 
E, Dreano M, Sirvent N, Peyron JF.. Targeting NF-kappaB 
activation via pharmacologic inhibition of IKK2-induced 
Insight in inflammation and cancer Omabe M, Kenneth NO 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2014; 18(3) 215 
apoptosis of human acute myeloid leukemia cells. Blood. 
2005 Jan 15;105(2):804-11. Epub 2004 Sep 28. 
Hoffman ES, Smith RE, Renaud RC Jr.. From the analyst's 
couch: TLR-targeted therapeutics. Nat Rev Drug Discov. 
2005 Nov;4(11):879-80. 
Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, 
Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, 
Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, 
Fridman WH, Galon J.. Effector memory T cells, early 
metastasis, and survival in colorectal cancer. N Engl J 
Med. 2005 Dec 22;353(25):2654-66. 
Roach JC, Glusman G, Rowen L, Kaur A, Purcell MK, 
Smith KD, Hood LE, Aderem A.. The evolution of 
vertebrate Toll-like receptors. Proc Natl Acad Sci U S A. 
2005 Jul 5;102(27):9577-82. Epub 2005 Jun 23. 
Borowsky AD, Dingley KH, Ubick E, Turteltaub KW, Cardiff 
RD, Devere-White R.. Inflammation and atrophy precede 
prostatic neoplasia in a PhIP-induced rat model. 
Neoplasia. 2006 Sep;8(9):708-15. 
De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, 
Drake CG, Nakai Y, Isaacs WB, Nelson WG.. Inflammation 
in prostate carcinogenesis. Nat Rev Cancer. 2007 
Apr;7(4):256-69. (REVIEW) 
Nibbs RJ, Gilchrist DS, King V, Ferra A, Forrow S, Hunter 
KD, Graham GJ.. The atypical chemokine receptor D6 
suppresses the development of chemically induced skin 
tumors. J Clin Invest. 2007 Jul;117(7):1884-92. 
Rakoff-Nahoum S, Medzhitov R.. Regulation of 
spontaneous intestinal tumorigenesis through the adaptor 
protein MyD88. Science. 2007 Jul 6;317(5834):124-7. 
Lerebours F, Vacher S, Andrieu C, Espie M, Marty M, 
Lidereau R, Bieche I.. NF-kappa B genes have a major 
role in inflammatory breast cancer. BMC Cancer. 2008 Feb 
4;8:41. doi: 10.1186/1471-2407-8-41. 
Swann JB, Vesely MD, Silva A, Sharkey J, Akira S, 
Schreiber RD, Smyth MJ.. Demonstration of inflammation-
induced cancer and cancer immunoediting during primary 
tumorigenesis. Proc Natl Acad Sci U S A. 2008 Jan 
15;105(2):652-6. doi: 10.1073/pnas.0708594105. Epub 
2008 Jan 4. 
Borroni EM, Buracchi C, Savino B, Pasqualini F, Russo 
RC, Nebuloni M, Bonecchi R, Mantovani A, Locati M.. Role 
of the chemokine scavenger receptor D6 in balancing 
inflammation and immune activation. Methods Enzymol. 
2009;460:231-43. doi: 10.1016/S0076-6879(09)05211-2. 
Camus M, Tosolini M, Mlecnik B, Pages F, Kirilovsky A, 
Berger A, Costes A, Bindea G, Charoentong P, Bruneval 
P, Trajanoski Z, Fridman WH, Galon J.. Coordination of 
intratumoral immune reaction and human colorectal cancer 
recurrence. Cancer Res. 2009 Mar 15;69(6):2685-93. doi: 
10.1158/0008-5472.CAN-08-2654. Epub 2009 Mar 3. 
de Jong RA, Leffers N, Boezen HM, ten Hoor KA, van der 
Zee AG, Hollema H, Nijman HW.. Presence of tumor-
infiltrating lymphocytes is an independent prognostic factor 
in type I and II endometrial cancer. Gynecol Oncol. 2009 
Jul;114(1):105-10. doi: 10.1016/j.ygyno.2009.03.022. Epub 
2009 May 2. 
Singh S, Sadanandam A, Nannuru KC, Varney ML, Mayer-
Ezell R, Bond R, Singh RK.. Small-molecule antagonists 
for CXCR2 and CXCR1 inhibit human melanoma growth 
by decreasing tumor cell proliferation, survival, and 
angiogenesis. Clin Cancer Res. 2009 Apr 1;15(7):2380-6. 
doi: 10.1158/1078-0432.CCR-08-2387. Epub 2009 Mar 17. 
Takahashi H, Ogata H, Nishigaki R, Broide DH, Karin M.. 
Tobacco smoke promotes lung tumorigenesis by triggering 
IKKbeta- and JNK1-dependent inflammation. Cancer Cell. 
2010 Jan 19;17(1):89-97. doi: 10.1016/j.ccr.2009.12.008. 
Aoi J, Endo M, Kadomatsu T, Miyata K, Nakano M, 
Horiguchi H, Ogata A, Odagiri H, Yano M, Araki K, Jinnin 
M, Ito T, Hirakawa S, Ihn H, Oike Y.. Angiopoietin-like 
protein 2 is an important facilitator of inflammatory 
carcinogenesis and metastasis. Cancer Res. 2011 Dec 
15;71(24):7502-12. doi: 10.1158/0008-5472.CAN-11-1758. 
Epub 2011 Oct 31. 
Cheng WL, Wang CS, Huang YH, Tsai MM, Liang Y, Lin 
KH.. Overexpression of CXCL1 and its receptor CXCR2 
promote tumor invasion in gastric cancer. Ann Oncol. 2011 
Oct;22(10):2267-76. doi: 10.1093/annonc/mdq739. Epub 
2011 Feb 22. 
Omabe M, Ezeani M.. Infection, inflammation and prostate 
carcinogenesis. Infect Genet Evol. 2011 Aug;11(6):1195-8. 
doi: 10.1016/j.meegid.2011.03.002. Epub 2011 Mar 21. 
(REVEW) 
Omabe M, Okorocha EA.. Molecular basis of cancer 
initiation. The International Journal of Biotechnology & 
Biochemistry (IJBB). 2011;7(2):229-38. 
Tazzyman S, Barry ST, Ashton S, Wood P, Blakey D, 
Lewis CE, Murdoch C.. Inhibition of neutrophil infiltration 
into A549 lung tumors in vitro and in vivo using a CXCR2-
specific antagonist is associated with reduced tumor 
growth. Int J Cancer. 2011 Aug 15;129(4):847-58. doi: 
10.1002/ijc.25987. Epub 2011 Apr 13. 
Betting DJ, Hurvitz SA, Steward KK, Yamada RE, Kafi K, 
van Rooijen N, Timmerman JM.. Combination of 
cyclophosphamide, rituximab, and intratumoral CpG 
oligodeoxynucleotide successfully eradicates established 
B cell lymphoma. J Immunother. 2012 Sep;35(7):534-43. 
doi: 10.1097/CJI.0b013e318261e679. 
Dewan MZ, Vanpouille-Box C, Kawashima N, DiNapoli S, 
Babb JS, Formenti SC, Adams S, Demaria S.. Synergy of 
topical toll-like receptor 7 agonist with radiation and low-
dose cyclophosphamide in a mouse model of cutaneous 
breast cancer. Clin Cancer Res. 2012 Dec 15;18(24):6668-
78. doi: 10.1158/1078-0432.CCR-12-0984. Epub 2012 Oct 
9. 
Garaude J, Kent A, van Rooijen N, Blander JM.. 
Simultaneous targeting of toll- and nod-like receptors 
induces effective tumor-specific immune responses. Sci 
Transl Med. 2012 Feb 8;4(120):120ra16. doi: 
10.1126/scitranslmed.3002868. 
Jamieson T, Clarke M, Steele CW, Samuel MS, Neumann 
J, Jung A, Huels D, Olson MF, Das S, Nibbs RJ, Sansom 
OJ.. Inhibition of CXCR2 profoundly suppresses 
inflammation-driven and spontaneous tumorigenesis. J 
Clin Invest. 2012 Sep 4;122(9):3127-44. doi: 
10.1172/JCI61067. Epub 2012 Aug 27. 
Li X, Liu D, Liu X, Jiang W, Zhou W, Yan W, Cen Y, Li B, 
Cao G, Ding G, Pang X, Sun J, Zheng J, Zhou H.. CpG 
ODN107 potentiates radiosensitivity of human glioma cells 
via TLR9-mediated NF-kB activation and NO production. 
Tumour Biol. 2012 Oct;33(5):1607-18. doi: 
10.1007/s13277-012-0416-1. Epub 2012 Jun 28. 
Lu H, Dietsch GN, Matthews MA, Yang Y, Ghanekar S, 
Inokuma M, Suni M, Maino VC, Henderson KE, Howbert 
JJ, Disis ML, Hershberg RM.. VTX-2337 is a novel TLR8 
agonist that activates NK cells and augments ADCC. Clin 
Cancer Res. 2012 Jan 15;18(2):499-509. doi: 
10.1158/1078-0432.CCR-11-1625. Epub 2011 Nov 29. 
Insight in inflammation and cancer Omabe M, Kenneth NO 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2014; 18(3) 216 
Omabe M, Ewenighi C, Ezeani M, Ogbonnaya K, Uzor S, 
Omabe O, Onyeanusi JC, Nnatuanya IN, Onoh LUM, 
Babatunde O.. Increasing Evidence for Cigarette Smoking 
and Prostate Cancer Progression in Eastern Nigeria. The 
International Journal of Biotechnology & Biochemistry 
(IJBB). 2012;8(2):61-69. 
Yoon SI, Kurnasov O, Natarajan V, Hong M, Gudkov AV, 
Osterman AL, Wilson IA.. Structural basis of TLR5-flagellin 
recognition and signaling. Science. 2012 Feb 
17;335(6070):859-64. doi: 10.1126/science.1215584. 
Bian G, Ding X, Leigh ND, Tang Y, Capitano ML, Qiu J, 
McCarthy PL, Liu H, Cao X.. Granzyme B-mediated 
damage of CD8+ T cells impairs graft-versus-tumor effect. 
J Immunol. 2013 Feb 1;190(3):1341-50. doi: 
10.4049/jimmunol.1201554. Epub 2012 Dec 21. 
Dovedi SJ, Melis MH, Wilkinson RW, Adlard AL, Stratford 
IJ, Honeychurch J, Illidge TM.. Systemic delivery of a 
TLR7 agonist in combination with radiation primes durable 
antitumor immune responses in mouse models of 
lymphoma. Blood. 2013 Jan 10;121(2):251-9. doi: 
10.1182/blood-2012-05-432393. Epub 2012 Oct 18. 
Dun EC, Hanley K, Wieser F, Bohman S, Yu J, Taylor RN.. 
Infiltration of tumor-associated macrophages is increased 
in the epithelial and stromal compartments of endometrial 
carcinomas. Int J Gynecol Pathol. 2013 Nov;32(6):576-84. 
doi: 10.1097/PGP.0b013e318284e198. 
Fang J, Seki T, Tsukamoto T, Qin H, Yin H, Liao L, 
Nakamura H, Maeda H.. Protection from inflammatory 
bowel disease and colitis-associated carcinogenesis with 
4-vinyl-2,6-dimethoxyphenol (canolol) involves 
suppression of oxidative stress and inflammatory 
cytokines. Carcinogenesis. 2013 Dec;34(12):2833-41. doi: 
10.1093/carcin/bgt309. Epub 2013 Sep 24. 
Jiang B, Mason J, Jewett A, Liu ML, Chen W, Qian J, Ding 
Y, Ding S, Ni M, Zhang X, Man YG.. Tumor-infiltrating 
immune cells: triggers for tumor capsule disruption and 
tumor progression? Int J Med Sci. 2013;10(5):475-97. doi: 
10.7150/ijms.5798. Epub 2013 Mar 5. 
Kim ST, Jeong H, Woo OH, Seo JH, Kim A, Lee ES, Shin 
SW, Kim YH, Kim JS, Park KH.. Tumor-infiltrating 
lymphocytes, tumor characteristics, and recurrence in 
patients with early breast cancer. Am J Clin Oncol. 2013 
Jun;36(3):224-31. doi: 10.1097/COC.0b013e3182467d90. 
Lopez JA, Susanto O, Jenkins MR, Lukoyanova N, Sutton 
VR, Law RH, Johnston A, Bird CH, Bird PI, Whisstock JC,  
Trapani JA, Saibil HR, Voskoboinik I.. Perforin forms 
transient pores on the target cell plasma membrane to 
facilitate rapid access of granzymes during killer cell 
attack. Blood. 2013 Apr 4;121(14):2659-68. doi: 
10.1182/blood-2012-07-446146. Epub 2013 Feb 1. 
Negi AK, Kansal S, Bhatnagar A, Agnihotri N.. Alteration in 
apoptosis and cell cycle by celecoxib and/or fish oil in 
7,12-dimethyl benzene (α) anthracene-induced mammary 
carcinogenesis. Tumour Biol. 2013 Dec;34(6):3753-64. 
doi: 10.1007/s13277-013-0959-9. Epub 2013 Sep 21. 
Peng J, Tsang JY, Li D, Niu N, Ho DH, Lau KF, Lui VC, 
Lamb JR, Chen Y, Tam PK.. Inhibition of TGF-β signaling 
in combination with TLR7 ligation re-programs a 
tumoricidal phenotype in tumor-associated macrophages. 
Cancer Lett. 2013 May 1;331(2):239-49. doi: 
10.1016/j.canlet.2013.01.001. Epub 2013 Jan 11. 
Omabe M, Onyekachi OB.. Dissecting The Biology of Solid 
Tumour: The Microenvironment and Cancer Progression. 
British Journal of Medicine & Medical Research. 
2013;3(4):1786-97. 
Tabriz HM, Olfati G, Ahmadi SA, Yusefnia S.. 
Cyclooxygenase-2 expression in urinary bladder 
transitional cell carcinoma and its association with 
clinicopathological characteristics. Asian Pac J Cancer 
Prev. 2013;14(8):4539-43. 
Vacchelli E, Eggermont A, Sautes-Fridman C, Galon J, 
Zitvogel L, Kroemer G, Galluzzi L.. Trial Watch: Toll-like 
receptor agonists for cancer therapy. Oncoimmunology. 
2013 Aug 1;2(8):e25238. Epub 2013 Jun 10. (REVIEW) 
Wilson JC, O'Rorke MA, Cooper JA, Murray LJ, Hughes 
CM, Gormley GJ, Anderson LA.. Non-steroidal anti-
inflammatory drug use and cervical cancer risk: A case-
control study using the Clinical Practice Research Datalink. 
Cancer Epidemiol. 2013 Dec;37(6):897-904. doi: 
10.1016/j.canep.2013.08.010. Epub 2013 Sep 14. 
Yuan H, Hsiao YH, Zhang Y, Wang J, Yin C, Shen R, Su 
Y.. Destructive impact of T-lymphocytes, NK and Mast 
cells on basal cell layers: implications for tumor invasion. 
BMC Cancer. 2013 May 25;13:258. doi: 10.1186/1471-
2407-13-258. 
This article should be referenced as such: 
Omabe M, Kenneth NO. Insight in inflammation and 
cancer. Atlas Genet Cytogenet Oncol Haematol. 2014; 
18(3):203-216. 
